Clinical Trial Update: Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events

View source ↗

Summary

A clinical trial update evaluating SGLT2 inhibitors and cardiovascular event risk in type 2 diabetes, reporting outcomes such as myocardial infarction, ischemic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Myocardial Infarction
• Stroke
• Type 2 Diabetes Mellitus

Drugs mentioned

• FARXIGA (dapagliflozin)
• INVOKANA (CANAGLIFLOZIN)
• Jardiance (empagliflozin)
• STEGLATRO (ertugliflozin)

Snippet

Sponsor: Canadian Network for Observational Drug Effect Studies, CNODES | Conditions: Type2 Diabetes, Myocardial Infarction | Status: COMPLETED